“…This suggests that ezrin may be a valuable prognostic biomarker and a potential therapeutic target. 11 In our study, Ezrin was not determined as a prognostic marker in endometrial cancers. But an extensive-expression was shown in atypical hyperplasia and endometrial cancer when compared to hyperplasia without atypia.…”